BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30059451)

  • 1. Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.
    Magrill J; Karnezis AN; Tessier-Cloutier B; Talhouk A; Kommoss S; Cochrane D; Chow C; Cheng A; Soslow R; Hauptmann S; du Bois A; Pfisterer J; Gilks CB; Huntsman DG; Kommoss F
    Int J Gynecol Pathol; 2019 Nov; 38(6):552-561. PubMed ID: 30059451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
    Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
    Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
    Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
    Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
    Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
    Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic features observation of ovarian transitional cell tumors].
    Wang L; Dong Y; Li Q; Li H; Sun X; Zhou X; Li X
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):118-22. PubMed ID: 25916643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
    Ali RH; Seidman JD; Luk M; Kalloger S; Gilks CB
    Int J Gynecol Pathol; 2012 Nov; 31(6):499-506. PubMed ID: 23018212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
    Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
    Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
    Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
    Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
    Esheba GE; Longacre TA; Atkins KA; Higgins JP
    Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
    Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
    Ruba S; Doherty D; Stewart CJR
    Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transitional cell carcinoma of the ovary. Morphological and clinical features].
    Kommoss F; Kommoss S; Eichhorn J; Schmidt D
    Pathologe; 2007 May; 28(3):209-14. PubMed ID: 17447068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens.
    Xu X; Sun TT; Gupta PK; Zhang P; Nasuti JF
    Cancer; 2001 Jun; 93(3):216-21. PubMed ID: 11391610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
    Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.